FindTrial
Sign In

Clinical Breakthrough of Gorlizatini in the Treatment of Elderly Frail Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma

Clinical Breakthrough of Gorlizatini in the Treatment of Elderly Frail Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600122969
Enrollment
Unknown
Registered
2026-04-20
Start date
2025-09-01
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angioimmunoblastic T-cell Lymphoma,AITL

Interventions

Observation group:None

Sponsors

Northern Jiangsu People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Patients diagnosed with recurrent refractory AITL and Frail by CGA assessment were enrolled in this study

Exclusion criteria

Exclusion criteria: PTCL patients without AITL or AITL patients with Fit or Vulnerable assessed by CGA

Design outcomes

Primary

MeasureTime frame
Efficacy;—

Secondary

MeasureTime frame
Safety;—

Countries

China

Contacts

Public ContactWang Fangfang

Northern Jiangsu People's Hospital

d160118@yzu.edu.cn+86 514 87373037

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026